- Conditions
- Enterocolitis Clostridium Difficile Recurrent
- Interventions
- RBX2660 (microbiota suspension), Placebo
- Biological · Other
- Lead sponsor
- Rebiotix Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Jacksonville, Florida + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Clostridium Difficile Infection (CDI)
- Interventions
- RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence)
- Drug
- Lead sponsor
- Rebiotix Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 60
- States / cities
- Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more
- Conditions
- Urinary Tract Infections
- Interventions
- Fecal microbiota transplant
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Clostridium Difficile Infection, Infection, Communicable Diseases
- Interventions
- RBX2660
- Drug
- Lead sponsor
- Rebiotix Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 793 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • North Little Rock, Arkansas • Oxnard, California + 43 more
- Conditions
- Clostridium Difficile Infection
- Interventions
- RBX2660, Standard of Care Antibiotics
- Biological · Drug
- Lead sponsor
- Rebiotix Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • North Little Rock, Arkansas • Sacramento, California + 25 more
- Conditions
- Recurrent Clostridium Difficile Infection
- Interventions
- RBX2660 (microbiota suspension)
- Biological
- Lead sponsor
- Rebiotix Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 8 more
- Conditions
- Clostridium Difficile Infection Recurrence
- Interventions
- RBX2660
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 12
- States / cities
- North Little Rock, Arkansas • Camarillo, California • Hamden, Connecticut + 9 more